Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma.
Chronic liver disease
Fatty liver
Liver cancer
Metabolic syndrome
Non-alcoholic fatty liver disease
Journal
JHEP reports : innovation in hepatology
ISSN: 2589-5559
Titre abrégé: JHEP Rep
Pays: Netherlands
ID NLM: 101761237
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
11
12
2022
revised:
23
03
2023
accepted:
18
05
2023
medline:
4
8
2023
pubmed:
4
8
2023
entrez:
4
8
2023
Statut:
epublish
Résumé
The metabolic dysfunction-associated fatty liver disease (MAFLD) is a new inclusive term proposed to replace non-alcoholic fatty liver disease (NAFLD). We analysed whether hepatocellular carcinoma (HCC) risk differs by MAFLD or NAFLD status in a large sample of asymptomatic adults. A cohort comprising 73,691 adults were followed up for the development of HCC. NAFLD was diagnosed among participants without other liver diseases (n = 65,992). Participants with MAFLD showed higher incidence of HCC than those without MAFLD (0.37 and 0.24 per 1,000 person-years, respectively; In patients with other chronic liver diseases, the presence of MAFLD is not independently associated with an increased risk of HCC. For those without other chronic liver diseases, MAFLD largely overlaps with NAFLD and is associated with an increased risk of HCC. This study investigated the usefulness of newly proposed nomenclature, metabolic dysfunction-associated fatty liver disease (MAFLD), over non-alcoholic fatty liver disease (NAFLD), in terms of predicting hepatocellular carcinoma. In patients with other chronic liver diseases, the presence of MAFLD is not independently associated with an increased risk of HCC. However, for those without chronic liver disease, MAFLD largely overlaps with NAFLD and is associated with an increased risk of HCC.
Sections du résumé
Background & Aims
UNASSIGNED
The metabolic dysfunction-associated fatty liver disease (MAFLD) is a new inclusive term proposed to replace non-alcoholic fatty liver disease (NAFLD). We analysed whether hepatocellular carcinoma (HCC) risk differs by MAFLD or NAFLD status in a large sample of asymptomatic adults.
Methods
UNASSIGNED
A cohort comprising 73,691 adults were followed up for the development of HCC. NAFLD was diagnosed among participants without other liver diseases (n = 65,992).
Results
UNASSIGNED
Participants with MAFLD showed higher incidence of HCC than those without MAFLD (0.37 and 0.24 per 1,000 person-years, respectively;
Conclusions
UNASSIGNED
In patients with other chronic liver diseases, the presence of MAFLD is not independently associated with an increased risk of HCC. For those without other chronic liver diseases, MAFLD largely overlaps with NAFLD and is associated with an increased risk of HCC.
Impact and Implications
UNASSIGNED
This study investigated the usefulness of newly proposed nomenclature, metabolic dysfunction-associated fatty liver disease (MAFLD), over non-alcoholic fatty liver disease (NAFLD), in terms of predicting hepatocellular carcinoma. In patients with other chronic liver diseases, the presence of MAFLD is not independently associated with an increased risk of HCC. However, for those without chronic liver disease, MAFLD largely overlaps with NAFLD and is associated with an increased risk of HCC.
Identifiants
pubmed: 37538246
doi: 10.1016/j.jhepr.2023.100810
pii: S2589-5559(23)00141-6
pmc: PMC10393797
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100810Informations de copyright
© 2023 The Author(s).
Déclaration de conflit d'intérêts
No potential conflict of interest relevant to this article was reported. Please refer to the accompanying ICMJE disclosure forms for further details.
Références
Nat Rev Gastroenterol Hepatol. 2022 Oct;19(10):638-651
pubmed: 35710982
J Hepatol. 2019 Mar;70(3):531-544
pubmed: 30414863
Lancet. 2014 Aug 30;384(9945):755-65
pubmed: 25129328
Clin Gastroenterol Hepatol. 2021 May;19(5):865-870
pubmed: 33453398
Endocrinol Metab (Seoul). 2014 Dec 29;29(4):405-9
pubmed: 25559568
Hepatology. 2017 Jan;65(1):54-64
pubmed: 27339817
Clin Mol Hepatol. 2022 Apr;28(2):150-163
pubmed: 34753279
Clin Mol Hepatol. 2022 Oct;28(4):790-801
pubmed: 35545437
J Gastroenterol Hepatol. 2017 Mar;32(3):667-676
pubmed: 27547913
J Hepatol. 2018 Oct;69(4):896-904
pubmed: 29886156
Obes Facts. 2016;9(2):65-90
pubmed: 27055256
Gastroenterology. 2020 May;158(7):1851-1864
pubmed: 32061595
Hepatology. 2013 Jun;57(6):2180-8
pubmed: 22996622
J Hepatol. 2017 Nov 02;:
pubmed: 29150142
Clin Mol Hepatol. 2021 Jan;27(1):157-174
pubmed: 33238333
Gut Liver. 2015 May 23;9(3):267-317
pubmed: 25918260
Cells. 2021 Aug 09;10(8):
pubmed: 34440803
Clin Mol Hepatol. 2019 Mar;25(1):52-64
pubmed: 30360031
Aliment Pharmacol Ther. 2022 Jan;55(1):97-107
pubmed: 34820871
Hepatol Int. 2021 Aug;15(4):892-900
pubmed: 34260013
Clin Mol Hepatol. 2021 Jul;27(3):363-401
pubmed: 34154309
Gastroenterology. 2018 Dec;155(6):1828-1837.e2
pubmed: 30144434
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
Hepatology. 2020 Mar;71(3):907-916
pubmed: 31309602
Diabetes Care. 2014 Jan;37 Suppl 1:S81-90
pubmed: 24357215
Clin Mol Hepatol. 2021 Apr;27(2):257-269
pubmed: 33751877
J Hepatol. 2020 Jul;73(1):202-209
pubmed: 32278004
Hepatology. 2021 Mar;73(3):1194-1198
pubmed: 32544255
Clin Gastroenterol Hepatol. 2021 Oct;19(10):2161-2171.e5
pubmed: 33137486
Eur Heart J. 2020 Apr 7;41(14):1384-1386
pubmed: 32259269
BMC Med. 2019 May 20;17(1):95
pubmed: 31104631
Eur Heart J. 2018 Sep 1;39(33):3021-3104
pubmed: 30165516
J Clin Gastroenterol. 2014 Feb;48(2):172-7
pubmed: 24402120
N Engl J Med. 2003 Apr 24;348(17):1625-38
pubmed: 12711737
Clin Mol Hepatol. 2019 Sep;25(3):283-293
pubmed: 30419649
Lancet. 2021 Jun 5;397(10290):2212-2224
pubmed: 33894145
J Infect Dis. 2021 Jul 15;224(2):294-302
pubmed: 33249474
Curr Diab Rep. 2020 Oct 5;20(11):59
pubmed: 33015726
Br Med J (Clin Res Ed). 1986 Jan 4;292(6512):13-5
pubmed: 3080046